ALBUPAD
Description:
After 6 years of research, the ALBUPAD start-up was officially founded in Strasbourg in 2023. Co-founded by Dr. Eya ALOUI (CEO), Dr. Jordan BEURTON (CTO), Dr. Benoît FRISCH, Dr. Philippe LAVALLE, and Prof. Pierre SCHAAF, ALBUPAD is developing an innovative breakthrough technology for manufacturing materials based on albumin, a protein produced naturally by the human body that is biocompatible, biodegradable and non-immunogenic.
At the origin of the project
ALBUPAD is based on the research work of Eya ALOUI, Doctor of Pharmacy and Doctor of Materials Chemistry, supervised by Dr Philippe LAVALLE (Biomaterials and Bioengineering laboratory, UMR_S 1121 / Inserm - University of Strasbourg) and Dr Benoît FRISCH (3Bio team of the CAMB laboratory, UMR 7199 / CNRS - University of Strasbourg).
Technology developed with the support of Carnot Mica, SATT Conectus, La Ligue contre le Cancer, Alsace contre le Cancer.